Prevention of the progression of precancerous lesions by vaccines is a virtually uncharted territory. Their potential, however, is being assessed in transgenic mice which develop autochthonous tumors with defined stages of progression. In this paper we show that the DNA micro-array technology significantly helps assessment of the preventive efficacy of a combined DNA and cell vaccine. All female rat Her-2/neu transgenic BALB/c (BALB-neuT) mice develop an invasive carcinoma in each of their mammary glands within 25 weeks of age. This is elicited by the activated transforming rat Her-2/neu oncogene embedded in their genome. We have previously shown that vaccination of mice bearing multiple in situ carcinomas with DNA plasmids which code for the extracellular and transmembrane domain of rat p185 neu , the product ofthe rat Her-2/neu oncogene, followed by a boost with rat p185 neu + allogeneic cells engineered to secrete interferon-j, keeps 48% of mice tumor free until week 32. We have now extended our follow-up until mice reach one year of age and show that protection vanishes as time progresses. This observation suggests that the accuracy of the results studying immunotherapy against life-threatening tumors is a function of the length of the follow-up. The application of microarrays, and the concordance of morphologic and gene expression data led us to identify antibody as the main mechanism induced by vaccination. Protection is associated with a break of tolerance and a limited autoimmunity against the Recent findings show that vaccines can prevent autochthonous tumors and block the progression of early preneoplastic lesions in Her-2/neu transgenic mice (1-5), and lend strength to the notion that efficient vaccination against tumor associated antigens (TAA) could be a way to forestall cancer in healthy individuals or those with preneoplastic lesions (6-8). The aim of cancer immunotherapy is to induce a rapid reaction against a life-threatening tumor. Immunoprevention is inspired by the need to maintain a constant surveillance against the occurrence of a likely, though not certain event (6). Its time frame may coincide with the subject's life. When lifelong control is envisaged, a substantial threat is posed by the escape ofTAA-loss clones. Its success may thus depend on the choice of the TAA against which the preventive reaction is elicited and the features of the neoplastic lesions (9).
Prevention of the progression of precancerous lesions by vaccines is a virtually uncharted territory. Their potential, however, is being assessed in transgenic mice which develop autochthonous tumors with defined stages of progression. In this paper we show that the DNA micro-array technology significantly helps assessment of the preventive efficacy of a combined DNA and cell vaccine. All female rat Her-2/neu transgenic BALB/c (BALB-neuT) mice develop an invasive carcinoma in each of their mammary glands within 25 weeks of age. This is elicited by the activated transforming rat Her-2/neu oncogene embedded in their genome. We have previously shown that vaccination of mice bearing multiple in situ carcinomas with DNA plasmids which code for the extracellular and transmembrane domain of rat p185 neu , the product ofthe rat Her-2/neu oncogene, followed by a boost with rat p185 neu + allogeneic cells engineered to secrete interferon-j, keeps 48% of mice tumor free until week 32. We have now extended our follow-up until mice reach one year of age and show that protection vanishes as time progresses. This observation suggests that the accuracy of the results studying immunotherapy against life-threatening tumors is a function of the length of the follow-up. The application of microarrays, and the concordance of morphologic and gene expression data led us to identify antibody as the main mechanism induced by vaccination. Protection is associated with a break of tolerance and a limited autoimmunity against the Recent findings show that vaccines can prevent autochthonous tumors and block the progression of early preneoplastic lesions in Her-2/neu transgenic mice (1) (2) (3) (4) (5) , and lend strength to the notion that efficient vaccination against tumor associated antigens (TAA) could be a way to forestall cancer in healthy individuals or those with preneoplastic lesions (6) (7) (8) . The aim of cancer immunotherapy is to induce a rapid reaction against a life-threatening tumor. Immunoprevention is inspired by the need to maintain a constant surveillance against the occurrence of a likely, though not certain event (6) . Its time frame may coincide with the subject's life. When lifelong control is envisaged, a substantial threat is posed by the escape ofTAA-loss clones. Its success may thus depend on the choice of the TAA against which the preventive reaction is elicited and the features of the neoplastic lesions (9) .
Immune prevention is concerned with not-yet tumors or preneoplastic lesions whose progression depends on the accumulation of gene mutations. Alterations of the protein component of a specific regulatory pathway provide early TAA responsible for a cell's transformed behavior. Priming of the immune response against these early TAA may elicit persistent protection, since their role in carcinogenesis limits the emergence of TAA-Ioss clones (10) . Moreover, in a hierarchy of events leading to tumor development, immune abrogation of cells expressing an early TAA can arrest carcinogenesis (11). The long dormancy of preneoplastic lesions and their slow proliferation further diminish the risk of the immune selection of TAA-loss clones. Moreover, the neoplastic behavior of these clones is hampered (12) until the accumulation of gene alterations makes their proliferation independent from the initial mutation.
Her-2/neu membrane product (p 185 ueu ) is a prototype of deregulated, oncogenic protein kinase, membrane receptors directly involved in cell carcinogenesis (13) . It is markedly overexpressed by early neoplastic lesions (14) (15) and plays crucial morphogenic roles in fetal life, but is poorly expressed in adults and in only a few tissues (16) . Overexpression of p 185 ueu may overcome self tolerance and make it a suitable target for both T-cell and antibody immune reactivity (17) (18) . Moreover, its interaction with antibody may regulate tumor cell behavior in ways not shared by conventional tumor antigens with no biological role in malignancy (1) (2) (3) (4) (5) 19) . However, it is a component of normal cell membranes in a few adult tissues and the risk of an autoimmune reaction must be taken into account. Because of its long time frame, immune prevention cannot be modeled on the results of short-term vaccination-tumor challenge experiments (8) . In investigation of the development of autochthonous carcinomas, too, the accuracy of the results is a function of the length of the follow-up (5) . Our studies of one of the most aggressive models of Her-2/neu multifocal mammary carcinogenesis have demonstrated that DNA priming followed by cell vaccine boosting significantly hampers the progression of preneoplastic lesions (4). We have now extended our follow-up until mice reach one year of age and show that protection vanishes as time progresses. Protection is associated with a break of tolerance to both trans gene rat and endogenous mouse p 185 ueu • A limited autoimmunity also changes the mammary gland structure.
MATERIALS AND METHODS

Additional information
Additional figures, tables, and normalized microarray data are available at http://www.bioinformatica.unito.it/ bioinformaticslFomi2/additional info/
Mice
Virgin BALB-neuT female mice (H-2d) of the same age overexpressing the transforming rat (2) Her-2/neu oncogene under the control of the MMTV (20) bred by us and treated according to the European Community guidelines were randomly assigned to the control and treatment groups, and all groups were specifically treated concurrently. Mammary glands were palpated at weekly intervals to note tumor appearance. Progressively growing masses> I mm mean diameter were regarded as tumors. Tumor multiplicity calculated as the cumulative number of incident tumors/total number ofmice is reported as mean ± SEM (20) . Differences in tumor incidence were evaluated with the Mantel-Haenszel log-rank test; differences in tumor multiplicity were evaluated with Student's t test.
Cells N202.1A cell clone (Neu/allo), whose cells express high levels ofrpl85 neu and H-2 q class I glycoproteins, was derived from a mammary carcinoma ofFVB-neuN#202 mice (H-2 Q ) , transgenic for the r neu protooncogene (2, 21) . Cells were stably transfected by calcium phosphate precipitation with a plasmid vector carrying the mouse IFN-y gene previously described (22) . Neu/allo-IFNy cells produced 700 ng/ml of IFN-y/24 hours/l x 10 5 seeded cells. BALB/c 3T3 fibroblasts were transfected with pRSVneo-K d (3T3 K cells) or cotransfected with pRSVneo-K d and pCMVratErbB-2 (3T3 NK cells) as previously described (23) . Clones of3T3 NK cells expressing high, stable levels of both genes were used for a second round of cotransfection with plasmid pEXV3murine B7-l and pcDNA3.l-Zeo and selected and cloned as previously described (23) to obtain 3T3 NKB cells.
Cells were cultured in Dulbecco's modified minimal essential medium (BioWhittaker, Walkerville, MD) supplemented with 20% fetal bovine serum (Life Technologies, Milan, Italy) at 37°C in a humidified 5% CO 2 atmosphere.
Prime and boost vaccination pcDNA3 vector coding the transmembrane and extracellular domain (TM-ECD) ofrpl85 ueu was produced as described 0, 24) . Plasmids (lOOllg/injection) were injected into the surgically exposed quadriceps muscle of anesthetized mice at week 10 and 12. At 13 weeks, mice received a subsequent intraperitoneal boost with 2 x 10 6 Neu/allo-IFNycells in 0,2 ml of PBS.
Morphologic and immunohistochemical analysis
Groups of three mice were sacrificed at the indicated times, and mammary tissue was processed as previously described (3, 15) for histological, immunohistochemical and whole mount analysis (http://ccm.ucdavis.edu/ tgmouse/HistoLab/who1mt1.htm). Morphologic studies were conducted independently by three pathologists in a blind fashion.
Whole mount image analysis
A Nikon Coolpix 950 digital camera (Nital spa, Turin, Italy) mounted on a stereoscopic Leica MZ 6 microscope (Leica Microsystems, Milan, Italy) with a 0.63 lens was used to yield images of whole-mount preparations with a total magnification of x 6.3 and a resolution of 1600 x 1200 pixels. Images were acquired within Adobe Photoshop v6.0 graphic software (Adobe Systems; San Jose, CA) running on a 1GHZ Pentium III PC with 512 MB of RAM. Glands larger than a single imaging area were captured by photographing contiguous microscopic fields in a raster pattern. Each captured image was merged with the layer technique in Adobe Photoshop to form a composite image for analysis. Spatial calibration was determined by photographing a l-mm stage micrometer, using the same parameters as for the image capturing. The distance drawn on the calibration image was divided by 1000 to find the number of pixels per micrometers. In each image 100 or more discrete points were randomly chosen on the duct surface and the width in micrometers of any lesion at that point was measured at right angles to the duct direction. A zero was assigned ifthere was no lesion. All measurements were recorded in an Excel spreadsheet and mean and SE were calculated for each treatment group. Statistical evaluation was performed with a two-tailed Student's t test.
The number of lesions with a diameter> 150 urn was also recorded for each gland.
Antibody response
Sera collected from mice at 14 weeks of age were analyzed by flow cytometry as described (1, 2) . Briefly, 1:20 dilutions of sera in PBS-azide-BSA were incubated with 2 x 10 5 3T3 NKB rp185"'u+ or 3T3 K p 185 ncu_ cells for 45 min at 4°. After washing, the cells were incubated for 30 min with rat biotin-conjugated Ab anti-mouse total Ig (Caltag Laboratories, Burlingame, CA) and then for 30 min with 5 III streptavidin-phycoeritrin (Dako), and resuspended in PBS-azide-BSA containing 1 mg/ml ofpropidium iodide and evaluated in a FACScan (Becton Dickinson, Mountain View, CA). The specific 3T3 NKB binding potential (Sbp) was calculated as follows: [(% positive cells with test serum)(fluorescence mean)] -[(% positive cells with control serum)(fluorescence mean)] x serum dilution (15) . 1 x 10 4 viable cells were analyzed in each evaluation. Differences in antibody titer were evaluated with Student's t test.
Immunoprecipitation and western blotting BALB/c mouse hearts were homogenized and lysed on ice in lysis buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, and 0.5% of Triton X-IOO) containing 10 ug/ml leupeptin, 10 ug/ml aprotinin, 1 mM phenylmethylsulfonylfluoride and 1 mM sodium orthovanadate (NaY04)' 3T3 NKB cells were solubilized on ice in the lysis buffer containing 1% NP40 instead of 0.5% of Triton X-100. Lysates were clarified for 15 min at 15,000g. Protein concentration was determined by the BCA protein assay (Pierce Biochemical Co., St. Louis, MO). Heart and cell lysates were precleared for 30 min with GammaBind Plus Sepharose (Pharmacia Biotech, Uppsala, Sweden), and then equilibrated in lysis buffer. Sepharoses (20 ul) , equilibrated in lysis buffer, were incubated either with immune sera diluted 1:10, or with 3 ug/ml of mAb Ab3 (Oncogene Research Products, Boston, MA) for heart lysate, or with 1.5 ug/ml of Ab4 (Oncogene Research Products) for cell lysate, on a rocker for 2 h at 4°C. After washings, sepharoses conjugated with Ab were incubated with precleared lysates (3 mg and 1 mg protein/sample for heart and cell extract, respectively) on a rocker for 3 hat 4°. After immunoprecipitation, immune complexes were washed, eluted, heated for 5 min at 95°in reducing Laemmli sample buffer and resolved in a 7.5% PAGE. Separated proteins were transferred to nitrocellulose membrane (Hybond C, Amersham, Little Chalfont, UK) and incubated at room temperature for 1 h with rabbit anti-Her-2/neu serum C-18 (3 ug/ml; Santa Cruz Biotechnology Inc, Santa Cruz, CA) followed by incubation at room temperature for 1 h with anti-rabbit Ig biotinylated species-specific whole Ab (1: 1500) and streptavidin-horseradish peroxidase conjugate (1: 400) (Amersham), and then visualized using the ECL detection system for rp 185 neu and the ECL plus detection system for mouse p185 neu (Amersham).
Microarray sample preparation
Total RNA (ttIRNA) was extracted and purified from mammary glands in transgenic mice as described in the Affymetrix manual (www.affymetrix.com). ttlRNAs were then spectrophotometrically quantified and inspected by denaturant agarose gel electrophoresis. Low-quality ttlRNAs were discarded and single animal ttlRNAs were pooled to obtain three replicates for the mammary glands of 22-week-old untreated BALB-neuT mice (wk22nt) and of 22-week-old primed and boosted BALB-neuT mice (wk22pb), and two for the mammary glands of 10-week-old untreated BALB-neuT mice (wkIOnt). cRNAs were generated and hybridized on 8 MG-U74A v2 Affimetrix DNA chips according to the Affymetrix protocol. Twenty ug ofttlRNA were used for the preparation of double-stranded cDNA using a Superscript choice system and an oligotdTjz-t-anchored T7 primer (Invitrogen, Carlsbad, CA). The cDNA was then used as a template to synthesize a biotinylated cRNA (5 h, 37°) with the aid of the BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics Inc., Santa Clara, CA). In vitro transcription products were purified on Rneasy spin columns (Qiagen, Milano, Italy). Biotinylated cRNA was then treated (35 min, 94°in a buffer composed of 200 mM Tris-acetate (pH 8.1), 500 mM potassium acetate, and 150 mM magnesium acetate. Affymetrix 8 MG-U74A array chips were hybridized with biotinylated cRNA (15 ug/chip, 16 h, 45°) using the hybridization buffer and control provided by the manufacturer (Affymetrix). GeneChip Fluidics station 400 (Affymetrix) was used to wash and stain the arrays. The standard protocol suggested by the manufacturer was used to detect the hybridized biotinylated cRNA. The chips were then scanned with a specific scanner (Affymetrix) to generate digitized image data (DAT files).
Microarray data analysis and clustering DAT files were analyzed by MAS 5.0 to generate background-normalized image data (CEL files). Probe set intensities were obtained by means of the GCRMA method (25) . The full data set was normalized according to the invariant set method (26) . Each experiment was subsequently standardized to have average 0 and standard A deviation I. The resulting data were analyzed in couple (wklOnt vs wk22pb; wklOnt vs wk 22nt; wk22pb vs wk 22nt) by SAM (27) using the two class unpaired sample method (full permutation, delta score ranging between I k-2.3 and fold change threshold 2: 2). The validity of the method was demonstrated by real-time RT-PCR evaluation of the expression of several cancer-related genes (not shown). GO classification (28) was performed with DAVID (http://david.niaid.nih.gov/david/) and over-represented functional GO families were identified using EASE annotation tool (29) . Type I statistical errors were corrected using the Benjamini method.
RESULTS
Carcinogenesis inhibition induced by a prime with TM-ECD plasmid and a boost with Neulallo-IFNy cells is temporary.
DNA vaccination with this plasmid at the 10th and 12th week of age, followed by a boost with Neu/allo-IFNy cells at week 13, when atypical hyperplasia and multiple in situ carcinomas are present, delays the development of palpable tumors and keeps 48% of the primed-and-boosted mice tumor-free until week 32 (4) . Repetition of this experiment with another 15 mice and a follow-up until week 52 ( Fig. I) showed that the protocol significantly (P < 0.00 I) delayed the first tumor appearance and more than doubled the disease-free survival, but all mice had developed at least one tumor by week 52 (Fig. lA) . Tumor multiplicity, too, was significantly reduced until week 35 (p<0.05) ( Fig. IB) , but reached 9 ± 2. TM-ECD plasmid vaccination alone at week 10 and 12 gave significantly less protection, while the injection of Neu/allo-IFNy cells alone at week 13 was ineffective ( Fig. lA and IB) .
Associated pathological events.
Carcinogenesis inhibition was assessed morphologically as in the previous experiment. On this occasion, however, the three sets of prototypic mammary lesions i) wklOnt glands with multifocal preneoplastic lesions; ii) wk22nt glands with invasive palpable carcinomas; iii) wk22pb glands, were evaluated by whole-mount image analysis. The size and number of lesions were much greater in wk22nt mice, whereas these parameters were identical in the other two sets (Tab. I) These results fit in well with the pattern observed in the previous experiment (4) and provide further evidence that carcinogenesis progression is halted in primed and boosted mice.
At week 42, progression became evident in the form of hyperplasia and carcinoma foci, especially near the nipples, and was accompanied by the return of immunological reactivity represented by the infiltration of some foci by reactive cells, both within and beyond the basal membrane between the neoplastic epithelial cells ( Fig. 2A) . rp 185neu was down-regulated in the cells and its expression was confined to the cytoplasm (Fig. 2B ). This reactivity, however, was not enough to impede tumor growth. This situation was associated with a simplified pattern of ductule fractal ramification (Fig. 3A) . Ductules were truncated as compared to age matched BALB/c mice ( Fig. 3A vs. 3B ).
Gene expression analysis ofthe mammary glands ofprimed and boosted mice.
We had previously compared the expression profiles of wklOnt, wk22nt and wk22pb with the physiological hyperplasia of 2-week-pregnant mice (4) . We now evaluated the differences between these three sets. The quality of the total RNA extracted from lymph-node-free mammary tissue from each mouse was assessed on denaturing agarose gel. Biological replicas were generated by pooling the high-quality total RNAs from three mice. These pools were used to synthesize biotinylated cRNAs for hybridization on 8 MG-U74A v2 Affymetrix (Santa Clara, CA) GeneChipsTM. The quality of the biological replicates was extremely good as the r' correlation coefficient was always higher then 0.97. The two class unpaired sample statistical method, implemented in SAM, was used to identify the differentially expressed genes between wklOnt vs wk22nt and between wk22pb vs wk22nt, producing 111 probe sets ( Fig. 4 , and see additional information A B Tab. I and II). The striking similarity between the gene expression profiles of wk 1Ont and wk22pb glands is denoted by the fact that the previously described SAM analysis showed only 4 probe sets (99850_at, XO 1857, IgE heavy chain constant region; 102076_at, AJ235940, IgVk aj4 gene; 97574J_at, AF036736, Immunoglobulin heavy chain variable region precursor gene; 101331_Cat, U55641, immunoglobulin kappa chain variable 28) different between the two experimental conditions. In agreement with (4), these four sets are related to immunoglobulin response (see additional information Tab. III). The Gene Ontology (GO) consortium produces three independent ontologies for gene products. The three ontologies form the basis for the description of the molecular function, biological process and cellular component of gene products. An ontology is a restricted structured vocabulary of terms that represent domain 
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knowledge. In a practical sense an ontology specifies a vocabulary that can be used to exchange queries and assertions. The 111 probe sets were divided into up ( Fig.  4A ) and down-modulated ( Fig. 4B ) with respect to wk22nt, and annotated using the gene ontology (GO) Biological process class (Fig. 5) .
It was also investigated if there were more interesting genes associated to a specific GO term than one might expect by chance. This question was answered using an Hypergeometric distribution (29) . We searched in our dataset for specific enrichment of Biological process and Molecular function GO families in the up and down-modulated genes. This analysis yielded, for the up-modulated genes, 3 over-represented and partially overlapping GO families (Tab. II) belonging to the Biological process class. No overrepresented GO family was identified in the downregulated group. The annotation is limited to the GO families containing 5 or more genes: transport» GO:00068I 0; response to pest/pathogen/parasite-GO:00096 I3; signal transduction> GO:000 7I 65; nucleobase, nucleoside. nucleotide and nucleic acid metabolism= GO:0006I39; cell proliferation» GO:0008283; response to biotic stimulus=GO:0009607. B: wk22pb/wkIOnt downmodulated genes versus wk22nt. The annotation is limited to the GO families containing 3 or more genes: cell adhesion» GO:0007I 55; transport» GO:00068 I 0; catabolism= GO:0009056; protein metabolism= GO:00I9538; signal transduction=GO:0007J65. Anti-pI85"'U specific antibodies in the sera of primed and boosted mice.
As expected (4), the gene expression analysis showed that the most prominent feature of the induced immune response in primed and boosted mice was a strong humoral response against the rp 185 0eu (4-5). Sera collected from primed and boosted 15week-old mice showed a high titer of antirp 185"CU specific antibody (Fig . 6 ), whereas it was much lower in mice vaccinated once or twice with DNA alone (Fig. 6A) , and almost marginal in those receiving Neu/allo-IFNy cells alone (not shown). Sera from primed and boosted mice also contained antibodies cross-reacting with mouse p 185"CU from heart tissue extracts of normal BALB/c mice, while no reactivity with these normal tissue extracts was evident with sera from mice receiving DNA vaccination alone (Fig. 6B) . Nevertheless, no pathological findings were discovered in the heart, kidney or liver of any primed and boosted BALB-neuT mice (not shown).
DISCUSSION
These new results show that the lifespan of the majority of BALB-neuT mice genetically predestined to die because of multiple mammary tumors is more than doubled by a specific vaccination performed when multifocal preneoplastic lesions are already evident in all their mammary glands. This suggests that established preneoplastic lesions are an appropriate target for a specific immunological attack and vaccination can be envisaged as an effective and soft prospect in the prevention of carcinogenesis due to the overexpression of Her-2/neu as well as other oncogenic growth factor receptors (6, 30) .
As indicated by the gene expression data and by the sera from immunized mice, the clearance of preneoplastic lesions is mainly due to a strong humoral immune response. The crucial importance of antibodies may be related to the role of rp 185 neu as both the target TAA and a membrane receptor regulating cell growth (30) . By down-regulating its expression on the cell membrane (5, 31) , and impeding its ability to form the homo-or heterodimers that spontaneously transduce proliferative signals (32) , antibodies may impede the progression of the cells that highly expresses rpl85 neu • Our previous studies have also shown that antip 185 neu antibodies hamper the three-dimensional growth ofHer-2/neu transgenic mammary carcinoma cells, while their rp185 neu loss variants lost short-term tumorigenicity (12) . The marked membrane downmodulation of rp 185 neu , its intracytoplasmic confinement and the morphological features of inhibited proliferation associated with diminished nuclear positivity of PCNA (4) (5) in the mammary glands of primed and boosted mice endorse this noncytotoxic role of anti p l85 neu antibody. However, these antibodies may also activate complement and mediate antibody-dependent cellular cytotoxity (5) .
The development of palpable tumors was substantially delayed in primed and boosted mice, though they all bore a tumor by the 44 th week. Our data suggest that tumor growth recommences after the 28 th week and is opposed by an ineffective reactivity. Direct infiltration by reactive cells of some neoplastic foci of long-surviving primed and boosted mice was never observed in mice receiving DNA vaccination only. Even after four DNA vaccinations the reactive cells did not get past the basal membrane and remained in the outskirts of the preneoplastic lesions (1, 24, 33) . Vaccination with Neu/allo-IFNy alone did not increase survival, while the resistance to carcinogenesis of DNA-immunized mice was only slightly enhanced by the injection of parental Neulallo cells (5) . Lastly proliferating or mytomycin-C treated Neu/allo cells provide a similar boosting (data not shown). Both alloantigen expression (34) and the local release of IFN-y (35) trigger a strong DTH-like reaction with the recruitment of many reactive leukocytes that results in the induction of a strong, but transient antitumor immune memory. Microarray analysis reveals virtual overlapping of the gene expression profiles ofwk22pb and wklOnt. GO annotation (Fig. 5) , though penalized by the presence of a limited amount of GO features belonging to the selected genes ( Fig 5 A: 45% unclassified in genes up-modulated in wklOnt and wk22pb versus wk22nt; fig. 5B : 27% unclassified in genes down-modulated in wklOnt and wk22pb versus wk22nt), indicates, as expected, the presence of metabolic differences and changes in the expression of genes related to signal transduction and cell proliferation pathways between the atypical hyperplasia (wklOnt and wk22pb) and the actively growing tumor (wk22nt). Furthermore, only in the up-modulated genes ( fig. 5 A) is it possible to observe the presence of genes related to humoral response (response to pest/pathogen/parasite, GO:0009613; response to biotic stimulus, GO:0009607). The presence of immunological events associated with the early phase of progression are further raised from the search for enrichment of GO functional classes. Overrepresentation of GO features related to humoral response was only in genes up-modulated between wk 1Ont and wk22pb versus wk22nt (Tab. II).
Halting of tumor progression observed in wk22pb by whole-mount image analysis has strong biological implications. As in other tumor systems, it may coincide with a definitive cure. However, the activated rat Her-2/neu oncogene is embedded in the genome of BALB-neuT mice and it is likely that neoplastic stem cells arise continuously. This makes the tumor-halting condition a dynamic result between rp 185"cu cell onset and their immunological clearance. Many interfering factors can alter the scales and allow tumor re-growth as the immune response fades .
. .
in agmg mice. The immune clearance of rp 185"cu cells is associated with a major alteration of the normal structure of the mammary gland. This indicates that they are involved in the branching of ductules and the formation of lobular structures. Since the antibodies elicited by vaccination cross-react with mouse p 185"CU, the elimination of mouse p I85"cU cells could also be expected. As autoimmunity cannot be easily dissociated from tumor immunity (36) (37) (38) (39) (40) , limited alteration of the mammary gland structure could be an acceptable price for carcinoma prevention. However, data from BALB/c mice demonstrate that both the structure of the gland and lactation (not shown) are not appreciably altered following this priming and boosting, and suggest that the immune alteration of the gland is restricted to cells overexpressing p 185"cu.
DNA priming followed by a boost with Neu/allo-IFNy cells successfully broke tolerance to an antigen markedly expressed during the third week of age and overexpressed by the multiple lesions present when immunization was started. The sustained antibody and cell-mediated reactivity elicited by priming and boosting stopped the devastating progression of these multiple lesions for many weeks. A similar active vaccination may be suggested for the management of the many persons diagnosed with a p 185"cu carcinoma in situ, since the combination of cellmediated and antibody responses is more effective than the antibody alone (41) (42) (43) . However, despite the many similarities of mammary carcinogenesis in BALB-neuT mice and women (15) , the mechanisms of tolerance to self p 185"eu could be different and the escape mechanisms of human preneoplastic lesions more difficult to overcome.
